Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 102 | 6,247 | 47% |
| 2020 | 83 | 5,369 | 49% |
| 2021 | 88 | 5,387 | 51% |
| 2022 | 86 | 4,927 | 53% |
| 2023 | 91 | 5,341 | 56% |
| 2024 | 86 | 5,501 | 58% |
| 2025 from claims | – | 5,858 5,364–6,216 | 59% |
| 2026 forecast | – | 5,992 5,274–6,888 | 59% |
| 2027 forecast | – | 6,048 5,172–7,172 | 59% |
| 2028 forecast | – | 6,102 5,095–7,430 | 60% |
| 2029 forecast | – | 6,156 5,031–7,672 | 60% |
| 2030 forecast | – | 6,210 4,978–7,903 | 61% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 32% of the cases CMS names in Pennsylvania; 43 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 46% inpatient hospital, 53% hospital outpatient, 1% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 101 | 6,040−4.1%/yr | −4.1%/yr | 3.4 | 1% | 6,410 in 2030+1%/yr |
| Massachusetts | 60 | 4,610+2.9%/yr | +2.9%/yr | 4.9 | 0% | 6,530 in 2030+6%/yr |
| New Jersey | 46 | 3,130−1%/yr | −1%/yr | 3.0 | 3% | 3,440 in 2030+1.6%/yr |
| Connecticut | 21 | 1,254−2.8%/yr | −2.8%/yr | 3.9 | 0% | 1,450 in 2030+2.4%/yr |
| New Hampshire | 10 | 688+1.5%/yr | +1.5%/yr | 3.1 | 0% | 920 in 2030+5%/yr |
| Maine | 6 | 387−3.6%/yr | −3.6%/yr | 2.5 | 0% | 440 in 2030+2.2%/yr |
| Rhode Island | 5 | 246−4.6%/yr | −4.6%/yr | 2.8 | 0% | 240 in 2030−0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 915 | 165,227−1.8%/yr | −1.8%/yr | 126.21.0× | 44% | 167,900 in 2030+0.3%/yr |
| Bronchoscopy & lung nodule | 75 | 5,292+1.2%/yr | +1.2%/yr | 3.91.5× | 0% | 7,300 in 2030+5.5%/yr |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Capsovision leads with 30% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 18 companies reported engagement with Pennsylvania’s surgeons worth $280K in consulting, speaking, meals and travel tied to these products, about $3,251 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.